Why the study?
Patients with post-traumatic stress disorder face increased cardiovascular risk, prompting examination of shared genetic regions between PTSD and cardiovascular conditions, imaging traits, and health behaviors.
Does post-traumatic stress disorder share genetic architecture and causal variants with cardiovascular conditions?
Does post-traumatic stress disorder share genetic architecture and causal variants with cardiovascular conditions?
PTSD and cardiovascular conditions share distinct genetic risk loci and tissue-specific mechanisms, highlighting neuronal, immune, and metabolic pathways that could serve as repurposed drug targets.
Shared genetic correlations between PTSD and CV traits are hypothesis-generating; prospective studies needed before informing risk models or interventions.
Patients with post-traumatic stress disorder face increased cardiovascular risk. This study examines shared genetic regions between post-traumatic stress disorder and 246 cardiovascular conditions across electronic health records, 82 cardiac imaging, and health behaviors defined by Life’s Essential 8. Post-traumatic stress disorder is genetically correlated with cardiovascular diagnoses in 33 regions, imaging traits in 4 regions, and health behaviors in 44 regions. Potentially shared causal variants between post-traumatic stress disorder and 17 cardiovascular conditions were observed in 11 regions. Subsequent observational analysis in AllofUS cohort showed post-traumatic stress disorder is associated with 13 diagnoses even after accounting for socioeconomic factors and depression. Genetically regulated proteome expression in brain and blood tissues identified 33 blood and 122 brain genes shared between the two conditions, revealing neuronal, immune, metabolic, and calcium-related mechanisms, with several genes as targets for existing drugs. These findings exhibit shared risk loci and genes are involved in tissue-specific mechanisms. Study shows PTSD predisposition shares distinct genes and genomic regions with several cardiovascular conditions. Here the findings reveal neuronal, immune, and metabolic pathways, and repurposed drug targets that further the understanding of the comorbidity.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: